![Logo for Syngene International Limited](/_next/image?url=https%3A%2F%2Ffiles.quartr.com%2Fcompany-icons%2FSquare%25201x%2FSyngene%2520International%2520Limited%2520-%2520Square.png&w=256&q=100)
Syngene International Investor Relations Material
Latest events
![Logo for Syngene International Limited](/_next/image?url=https%3A%2F%2Ffiles.quartr.com%2Fcompany-icons%2FSquare%25201x%2FSyngene%2520International%2520Limited%2520-%2520Square.png&w=128&q=100)
Q1 24/25
Syngene International
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Syngene International Limited
Access all reports
Syngene International Ltd engages in the provision of contract research and manufacturing services to the pharmaceutical, nutrition, and plant biology industries. It offers a comprehensive range of services from discovery support to manufacture of life-enabling therapies.
The company is involved in three principal activities: providing drug discovery research services; drug development services; and manufacture of active pharmaceutical ingredients & Intermediates, Recombinant proteins, Bioagrochemicals, Biosimilars & Biogenerics and also offering third party research & manufacturing services, including custom synthesis projects. The company was incorporated in 1993 and is headquartered in Bengaluru, India.
Key slides for Syngene International Limited
![Key facts and figure](/_next/image?url=https%3A%2F%2Fcdn.quartr.com%2Fimages%2Fconference-calls%2Fsyngene-international-limited-q1-2425-efc80a743f760537%2F10.png&w=3840&q=75)
![Logo for Syngene International Limited](/_next/image?url=https%3A%2F%2Ffiles.quartr.com%2Fcompany-icons%2FSquare%25201x%2FSyngene%2520International%2520Limited%2520-%2520Square.png&w=128&q=100)
Q1 24/25
Syngene International Limited
![Robust risk manageme](/_next/image?url=https%3A%2F%2Fcdn.quartr.com%2Fimages%2Fconference-calls%2Fsyngene-international-limited-q1-2425-efc80a743f760537%2F27.png&w=3840&q=75)
![Logo for Syngene International Limited](/_next/image?url=https%3A%2F%2Ffiles.quartr.com%2Fcompany-icons%2FSquare%25201x%2FSyngene%2520International%2520Limited%2520-%2520Square.png&w=128&q=100)
Q1 24/25
Syngene International Limited
Latest articles
![Key](/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F182663%2F2000x1125%2Fbbbaafadba%2Fpontis-dackmo_strong-opinions-loosely-held.png&w=3840&q=75)
Strong Opinions, Loosely Held: Pontus Dackmo on Flexibility and Market Psychology
After a two-decade career in finance, Pontus Dackmo co-founded Protean Funds Scandinavia in 2022, where he now serves as CEO and Investment Manager.
4 Sep 2024
![Key](/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F182663%2F2000x1125%2F7455f6afd1%2Fnovo-nordisk_the-danish-pharmaceutical-titan.png&w=3840&q=75)
Novo Nordisk: The Danish Pharmaceutical Titan Revolutionizing Global Healthcare
Novo Nordisk's rise to becoming Europe's largest company, reshaping global healthcare and Denmark's economy.
5 Sep 2024
![Key](/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F182663%2F2000x1125%2F5533bee49f%2Fthe-toyota-way.png&w=3840&q=75)
The Toyota Way: Revolutionizing Global Manufacturing
Explore how Toyota's Lean Manufacturing and Kaizen principles revolutionized production and quality, setting global benchmarks for excellence.
2 Sep 2024
Ticker symbol
SYNGENE
Country
🇮🇳 India